Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Drimia maritima
Bulbous Mediterranean plant of coastal areas; bulb used in historical medicine as cardiac glycoside source and expectorant; related to digitalis.
Scilla squill (Drimia maritima) is a Mediterranean bulb historically employed as a cardiotonic and expectorant, with use dating back to ancient Egyptian medicine. Its primary active compounds include cardiac glycosides such as scillaren A, proscillaridin A, and glucoscillaren A, which exert digitalis-like effects on myocardial contractility. Modern applications are restricted to standardized pharmaceutical preparations due to a narrow therapeutic index and significant toxicity.
The cardiac glycosides in squill inhibit the Na+/K+-ATPase pump in cardiac myocytes, leading to increased intracellular sodium and subsequent calcium influx via the Na+/Ca2+ exchanger, thereby enhancing myocardial contractility (positive inotropy). Additionally, these compounds exert vagomimetic effects, slowing heart rate and atrioventricular conduction. The expectorant action is attributed to saponin-induced irritation of gastric mucosa, which reflexively stimulates bronchial secretions. The rodenticidal activity of red squill (scilliroside) is due to selective toxicity in rodents, while humans experience emesis at sublethal doses.
Bulbous Mediterranean plant of coastal areas; bulb used in historical medicine as cardiac glycoside source and expectorant; related to digitalis.
Scilla squill (Drimia maritima) is a Mediterranean bulb historically employed as a cardiotonic and expectorant, with use dating back to ancient Egyptian medicine. Its primary active compounds include cardiac glycosides such as scillaren A, proscillaridin A, and glucoscillaren A, which exert digitalis-like effects on myocardial contractility. Modern applications are restricted to standardized pharmaceutical preparations due to a narrow therapeutic index and significant toxicity.
The cardiac glycosides in squill inhibit the Na+/K+-ATPase pump in cardiac myocytes, leading to increased intracellular sodium and subsequent calcium influx via the Na+/Ca2+ exchanger, thereby enhancing myocardial contractility (positive inotropy). Additionally, these compounds exert vagomimetic effects, slowing heart rate and atrioventricular conduction. The expectorant action is attributed to saponin-induced irritation of gastric mucosa, which reflexively stimulates bronchial secretions. The rodenticidal activity of red squill (scilliroside) is due to selective toxicity in rodents, while humans experience emesis at sublethal doses.